CTOs on the Move

GoHealth Urgent Care

www.gohealthuc.com

 
GoHealth Urgent Care is one of the countrys fastest-growing and largest urgent care providers. At GoHealth Urgent Care, we place the needs of our patients first—by providing an effortless patient experience, a welcoming culture of care and seamless integration with market-leading health systems and our communities. GoHealth Urgent Care operates 80 urgent care centers in the New York and Portland, Oregon, metropolitan areas, the San Francisco Bay Area, Hartford, Connecticut, and will soon open urgent care centers in multiple Midwest markets. GoHealth Urgent Cares current partners include health systems that are at the forefront of care delivery innovation, including Northwell ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million
  • www.gohealthuc.com
  • 5555 Glenridge Connector Suite 700
    Atlanta, GA USA 30342
  • Phone: 678.774.7100

Executives

Name Title Contact Details
Dan Golden
Vice President, Information Systems Profile
Andrew Neumann
Chief Information Officer Profile
Dev Ashish
Chief Information Officer Profile

Similar Companies

Fairmont General Hospital

Fairmont General Hospital is a private, non-profit, community hospital founded in 1939. The hospital provides a wide variety of patient services and is accredited by the Joint Commission and the American College of Surgeons Commission on Cancer.

Renal Solutions

Renal Solutions is a Warrendale, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Smc Health Resources Inc

Smc Health Resources Inc is a Fairfield, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Occupational Health Research

Occupational Health Research is a Skowhegan, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.